Diferencia entre revisiones de «Sildenafil»
(Created page with "==Administration== *Type: PDE-5 inhibitor *Dosage Forms: *Routes of Administration: PO, IV *Common Trade Names: Viagra, Revatio ==Adult Dosing== *Pulmonary hypertension: 5-20...") |
|||
| (No se muestra una edición intermedia de otro usuario) | |||
| Línea 3: | Línea 3: | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: PO, IV | *Routes of Administration: PO, IV | ||
*Common Trade Names: Viagra, Revatio | *Common Trade Names: Viagra, [https://fildena.net Fildena], Revatio | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Línea 22: | Línea 22: | ||
*Concurrent regular or intermittent use of any organic nitrates | *Concurrent regular or intermittent use of any organic nitrates | ||
*Concomitant use with HIV protease inhibitors or elvitegravir/cobicistat/tenofovir/emtricitabine | *Concomitant use with HIV protease inhibitors or elvitegravir/cobicistat/tenofovir/emtricitabine | ||
*Concomitant use with riociguat or any other guanylate cyclase stimulator | *Concomitant use with [[riociguat]] or any other guanylate cyclase stimulator | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Línea 45: | Línea 45: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Inhibits cGMP specific phosphodiesterase type-5 (PDE5) in smooth | *Inhibits cGMP specific phosphodiesterase type-5 (PDE5) in smooth muscle→ less cGMP breakdown→ more cGMP within vascular smooth muscle→ vascular smooth muscle relaxation→ vasodilation | ||
==Comments== | ==Comments== | ||
Revisión actual - 18:47 8 mar 2018
Administration
- Type: PDE-5 inhibitor
- Dosage Forms:
- Routes of Administration: PO, IV
- Common Trade Names: Viagra, Fildena, Revatio
Adult Dosing
- Pulmonary hypertension: 5-20mg PO TID or 2.5-10 mg IV bolus TID
- Erectile dysfunction: 25-100mg PO 1hr prior to sexual activity, max once daily
Pediatric Dosing
Not generally recommended for chronic use in pediatric patients, but is used off-label
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment for mild-moderate impairment
Contraindications
- Allergy to class/drug
- Concurrent regular or intermittent use of any organic nitrates
- Concomitant use with HIV protease inhibitors or elvitegravir/cobicistat/tenofovir/emtricitabine
- Concomitant use with riociguat or any other guanylate cyclase stimulator
Adverse Reactions
Serious
- Myocardial infaction
- Sickle cell vasoocclusive crisis
- Ischemic optic neuropathy, retinal hemorrhage
- Hearing loss
- Priapism
Common
- Headache
- Insomnia
- Visual disturbance
- Erythema, flushing
- Indigestion
- Epistaxis, nasal congestion, rhinorrhea
Pharmacology
- Half-life: 4h
- Metabolism: Hepatic: CYP3A4 (major) and CYP2C9 (minor)
- Excretion: Mostly fecal
Mechanism of Action
- Inhibits cGMP specific phosphodiesterase type-5 (PDE5) in smooth muscle→ less cGMP breakdown→ more cGMP within vascular smooth muscle→ vascular smooth muscle relaxation→ vasodilation